en

PRODUCT DETAIL

MVASI 25 mg/ml infúzny koncentrát

Code 7323C
MA number EU/1/17/1246/001
Product Form: con inf 1x4 ml/100 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
L01FG01 Bevacizumab
Shelf life: 24
Container: glass vial
Route of admin.: Intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(4) similar biological application
MA issued: 15.01.2018
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 17.10.2022
eu-flag.png sk-flag.png